CGEN Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Compugen Ltd had $72.8M of revenue in fiscal 2025, up 161.1% on the year before. Over five years, revenue changed +105.2% a year on average.
Hi! I read Compugen Ltdβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+161.1%
Yes. Sales grew 161.1% last year.
Does it make a profit?
48.6%
Yes. It keeps 48.6% of every sale as profit.
Does profit turn into cash?
43.1%
Yes. 43.1% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Compugen Ltd did it, and the next one. Share prices often move a lot on those days.
Next results
November 9, 2026
Monday Β· in 14 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Mar 2, 2026 | Period ended Dec 31, 2025 | Before the market opens | 20-F β |
| Mar 4, 2025 | Period ended Dec 31, 2024 | Before the market opens | 20-F β |
| Mar 5, 2024 | Period ended Dec 31, 2023 | After the market closes | 20-F β |
| Feb 28, 2023 | Period ended Dec 31, 2022 | Before the market opens | 20-F β |
| Feb 28, 2022 | Period ended Dec 31, 2021 | Before the market opens | 20-F β |
| Feb 25, 2021 | Period ended Dec 31, 2020 | After the market closes | 20-F β |
| Feb 24, 2020 | Period ended Dec 31, 2019 | Before the market opens | 20-F β |
| Mar 21, 2019 | Period ended Dec 31, 2018 | Before the market opens | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Compugen Ltd had $72.8M of revenue in fiscal 2025, up 161.1% on the year before. Over five years, revenue changed +105.2% a year on average. Its operating margin was 43.1%, up 96.5Β pts: of every 100 in sales, about 43 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Compugen Ltd made $35.3M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $31.3M in fiscal 2025, 43.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Compugen Ltd can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.8M | $11.1M | $25.6M | $41.9M | $99.9M |
| Current ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Quick ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Total assets | $132M | $94.2M | $121M | $115M | $157M |
| Total liabilities | $25.5M | $16.5M | $55.8M | $60.1M | $53.8M |
| Shareholders' equity | $107M | $77.7M | $65.6M | $54.9M | $103M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Compugen Ltd passes 6 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | 2 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 6 / 8 |
| Accruals ratio | β16.4% | β11.7% | β20.3% | 1.0% | β1.4% | β8.5% | 0.4% | 15.9% | β54.0% | 2.7% |
| Altman Z'' | β1.40 | β24.94 | β16.25 | β18.06 | 1.74 | β2.53 | β8.19 | β7.46 | β8.87 | β0.84 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.7M | β | $17.8M | β | $2.0M | $6.0M | $7.5M | $33.5M | $27.9M | $72.8M |
| Gross profit | $0.5M | β | $16.8M | β | $1.9M | $5.3M | $6.5M | $31.5M | $19.9M | $63.5M |
| Research and development | $24.5M | $28.6M | $30.3M | $19.8M | $22.8M | $28.7M | $30.6M | $34.5M | $24.8M | $22.8M |
| Operating income | β$32.6M | β$37.4M | β$23.2M | β$28.9M | β$31.5M | β$35.1M | β$35.4M | β$13.0M | β$14.9M | $31.3M |
| Pretax income | β$31.5M | β$37.1M | β$22.6M | β$28.1M | β$29.7M | β$34.2M | β$33.6M | β$9.8M | β$9.7M | $35.4M |
| Income tax | $0.0M | β | β | β$0.7M | $0.0M | $0.0M | $0.1M | $9.0M | $4.5M | $0.1M |
| Net income | β$31.5M | β$37.1M | β$22.6M | β$27.3M | β$29.7M | β$34.2M | β$33.7M | β$18.8M | β$14.2M | $35.3M |
| Net income to common | β | β | β | β | β | β | β | β$18.8M | β$14.2M | $35.3M |
| Diluted EPS | β$0.62 | β$0.72 | β$0.41 | β$0.43 | β$0.37 | β$0.41 | β$0.39 | β$0.21 | β$0.16 | $0.38 |
| Diluted shares | 0.05B | 0.05B | 0.06B | 0.06B | 0.08B | 0.08B | 0.09B | 0.09B | 0.09B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$19.8M | β$30.7M | β$13.3M | β$27.9M | β$28.3M | β$22.7M | β$34.1M | β$35.9M | $49.6M | $31.6M |
| Capital expenditure | $2.6M | $0.4M | $0.2M | $0.2M | $0.2M | $0.3M | $0.5M | $0.2M | $0.1M | $0.3M |
| Free cash flow | β$22.4M | β$31.0M | β$13.4M | β$28.0M | β$28.5M | β$23.0M | β$34.6M | β$36.1M | $49.5M | $31.3M |
| Depreciation and amortization | $1.5M | $1.6M | $1.4M | $1.0M | $0.7M | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M |
| Stock-based compensation | $3.1M | $2.6M | $2.2M | $2.4M | $2.8M | $4.3M | $4.3M | $3.6M | $3.0M | $1.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $9.7M | $25.5M | $5.9M | $9.2M | $7.1M | $7.8M | $11.1M | $25.6M | $41.9M | $99.9M |
| Current assets | $62.7M | $31.2M | $46.6M | $45.0M | $129M | $123M | $86.1M | $115M | $106M | $148M |
| Current liabilities | $4.7M | $6.2M | $10.0M | $6.8M | $10.5M | $17.1M | $11.9M | $26.3M | $20.2M | $22.6M |
| Property and equipment, net | $6.0M | $4.6M | $3.4M | $2.3M | $1.7M | $1.7M | $1.5M | $1.2M | $0.9M | $0.7M |
| Total assets | $71.1M | $38.7M | $53.2M | $53.8M | $138M | $132M | $94.2M | $121M | $115M | $157M |
| Total liabilities | $7.6M | $9.4M | $15.9M | $15.4M | $18.5M | $25.5M | $16.5M | $55.8M | $60.1M | $53.8M |
| Shareholders' equity | $63.5M | $29.3M | $37.2M | $38.3M | $120M | $107M | $77.7M | $65.6M | $54.9M | $103M |
| Margins | ||||||||||
| Gross margin | 68.7% | β | 94.2% | β | 97.0% | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating margin | β4,576.3% | β | β130.5% | β | β1,574.8% | β584.6% | β471.7% | β38.8% | β53.4% | 43.1% |
| EBITDA margin | β4,367.8% | β | β122.7% | β | β1,539.1% | β576.9% | β465.2% | β37.4% | β51.7% | 43.7% |
| Net margin | β4,425.0% | β | β127.0% | β | β1,484.9% | β570.1% | β449.3% | β56.1% | β51.1% | 48.6% |
| FCF margin | β3,148.6% | β | β75.6% | β | β1,424.3% | β383.1% | β461.2% | β107.8% | 177.6% | 43.1% |
| Returns | ||||||||||
| Return on capital employed | β49.1% | β114.9% | β53.8% | β61.5% | β24.6% | β30.5% | β43.0% | β13.7% | β15.7% | 23.4% |
| Return on equity | β49.6% | β79.9% | β67.9% | β72.4% | β37.6% | β30.2% | β36.5% | β26.2% | β23.6% | 44.8% |
| Return on assets | β44.3% | β67.5% | β49.2% | β51.1% | β30.9% | β25.3% | β29.8% | β17.4% | β12.0% | 26.0% |
| Return on tangible equity | β49.6% | β126.5% | β60.7% | β71.3% | β24.8% | β32.1% | β43.4% | β28.6% | β25.9% | 34.4% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | 200.0% | 25.0% | 346.1% | β16.7% | 161.1% |
| FCF growth | β | β | β | β | β | β | β | β | β | β36.7% |
| Share count change | β | 0.6% | 8.0% | 15.1% | 25.1% | 5.8% | 2.8% | 1.2% | 2.2% | 4.8% |
| Financial health | ||||||||||
| Current ratio | 13.2x | 5.0x | 4.7x | 6.6x | 12.3x | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Quick ratio | 13.2x | 5.0x | 4.7x | 6.6x | 12.3x | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 365.0% | β | 0.9% | β | 8.3% | 4.9% | 6.4% | 0.5% | 0.4% | 0.4% |
| Stock comp / revenue | 433.1% | β | 12.2% | β | 138.6% | 71.3% | 57.7% | 10.6% | 10.8% | 2.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | β | β | 2.0 | 2.0 | 3.0 | 4.0 | 6.0 |
| Altman Z'' | β1.4 | β24.9 | β16.2 | β18.1 | 1.7 | β2.5 | β8.2 | β7.5 | β8.9 | β0.8 |
| Accruals ratio | β16.4% | β11.7% | β20.3% | 1.0% | β1.4% | β8.5% | 0.4% | 15.9% | β54.0% | 2.7% |
Source: SEC EDGAR XBRL filings (CIK 0001119774). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
